ArticleJournal of nanobiotechnology2012
Targeting of ICAM-1 on vascular endothelium under static and shear stress conditions using a liposomal Gd-based MRI contrast agent.
Article in Journal of nanobiotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 78 citations in OpenAlex.
- Potential Applications of Rare Earth Metal Nanoparticles in Biomedicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Immunoliposomes for detection of rupture-prone intracranial aneurysms.Acta neurochirurgica · 2023Article
- Diagnostics of atherosclerosis: Overview of the existing methods.Frontiers in cardiovascular medicine · 2023Review
- Targeting vascular inflammation through emerging methods and drug carriers.Advanced drug delivery reviews · 2022Review
- Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications.Frontiers in pharmacology · 2022Review
- New Approaches in Nanomedicine for Ischemic Stroke.Pharmaceutics · 2021Review
- Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer.Journal of nanobiotechnology · 2020Article
- Microfluidics for studying metastatic patterns of lung cancer.Journal of nanobiotechnology · 2019Review
- Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases.Frontiers in bioengineering and biotechnology · 2019Review
- Effect of flow on targeting and penetration of angiopep-decorated nanoparticles in a microfluidic model blood-brain barrier.PloS one · 2018Article
- Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective.BioImpacts : BI · 2018Review
- ICAM-1-Targeted Liposomes Loaded with Liver X Receptor Agonists Suppress PDGF-Induced Proliferation of Vascular Smooth Muscle Cells.Nanoscale research letters · 2017Article
- Targeting cell adhesion molecules with nanoparticles using in vivo and flow-based in vitro models of atherosclerosis.Experimental biology and medicine (Maywood, N.J.) · 2017Review
- Vascular targeting of nanoparticles for molecular imaging of diseased endothelium.Advanced drug delivery reviews · 2017Review
- Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis.Advanced healthcare materials · 2015Review
- Interaction between drug delivery vehicles and cells under the effect of shear stress.Biomicrofluidics · 2015Article
- Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents.Nanomedicine (London, England) · 2015Review
- Characterization of a lanthanide complex encapsulated with MRI contrast agents into liposomes for biosensor imaging of redundant deviation in shifts (BIRDS).Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2014Article
- Targeted nanotechnology for cancer imaging.Advanced drug delivery reviews · 2014Review
- Preparation, characterization and in vitro efficacy of magnetic nanoliposomes containing the artemisinin and transferrin.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe upregulation of intercellular adhesion molecule-1 (ICAM-1) on the endothelium of blood vessels in response to pro-inflammatory stimuli is of major importance for the regulation of local inflammation in cardiovascular diseases such as atherosclerosis, myocardial infarction and stroke. In vivo molecular imaging of ICAM-1 will improve diagnosis and follow-up of patients by non-invasive monitoring of the progression of inflammation.
resultsA paramagnetic liposomal contrast agent functionalized with anti-ICAM-1 antibodies for multimodal magnetic resonance imaging (MRI) and fluorescence imaging of endothelial ICAM-1 expression is presented. The ICAM-1-targeted liposomes were extensively characterized in terms of size, morphology, relaxivity and the ability for binding to ICAM-1-expressing endothelial cells in vitro. ICAM-1-targeted liposomes exhibited strong binding to endothelial cells that depended on both the ICAM-1 expression level and the concentration of liposomes. The liposomes had a high longitudinal and transversal relaxivity, which enabled differentiation between basal and upregulated levels of ICAM-1 expression by MRI. The liposome affinity for ICAM-1 was preserved in the competing presence of leukocytes and under physiological flow conditions.
conclusionThis liposomal contrast agent displays great potential for in vivo MRI of inflammation-related ICAM-1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.